Synta Pharma (SNTA) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St futures ease as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges down against euro
Roth Capital Positive on Synta (SNTA) Following Q3 Results; Focus Remains on Ganetespib Phase III GALAXY-2
November 6, 2014 2:09 PM ESTRoth Capital affirms Synta Pharma (Nasdaq: SNTA) at Buy with a price target of $27 following Q3 results reported earlier on the session.
Synta Pharma reported Q3 loss of $0.19 per share, $0.05 better than the analyst loss estimate of $0.24 per share.
Analyst Joseph Pantginis noted that Synta announced the... More
